Table 1.

Key results from IDegLira Phase 3a and 3b trials [12,54,55–57].

	DUAL I [12]		DUAL II [53]	DUAL III [55]	DUAL IV [56]	DUAL V [57]
	IDegLira vs IDeg	IDegLira vs liraglutide	IDegLira vs IDeg	IDegLira vs unchanged GLP-1RA	IDegLira vs placebo	IDegLira vs insulin glargine
HbA1c change†, ETD, %-points	–0.47 (–0.58 to –0.36), p < 0.0001 (noninferior)	–0.64 (–0.75 to –0.53), p < 0.0001 (superior)	–1.1 (–1.3 to –0.8), p < 0.0001 (superior)	–0.94 (–1.11 to –0.78), p < 0.001 (superior)	–1.02%, p < 0.001	–0.59 (–0.74 to –0.45), p < 0.001
Fasting plasma glucose change†, ETD, mmol/l	–0.17 (–0.41 to 0.07), NS	–1.76 (–2.00 to –1.53), p < 0.0001	–0.73 (–0.19 to –0.27), p = 0.0019	–2.64 (–3.03 to –2.25), p < 0.001	–2.30, p < 0.001	–0.01 (–0.35 to –0.33), NS
Mean of postprandial plasma glucose increment across all main meals, ETD, mmol/l	–0.45 (–0.63 to –0.28), p < 0.0001	0.06 (–0.11 to 0.23), NS	–0.4 (–0.7 to –0.0) p = 0.0260	N/A	N/A	N/A
Weight change†, ETD, kg	–2.22 (–2.64 to –1.80), p < 0.0001	+2.44 (2.02–2.86), p < 0.0001	–2.5 (–3.2 to –1.8), p < 0.0001	2.89 (2.17–3.62], p < 0.001	N/A	–3.2 (–3.77 to –2.64), p < 0.001
Confirmed hypoglycemia‡, rate ratio	0.68 (0.53 to 0.87), p = 0.0023	7.61 (5.17 to 11.21), p < 0.0001	0.66 (0.39 to 1.13), NS	25.4 (10.6 to 60.5), p < 0.001	3.74, p < 0.001	0.43 (0.30 to 0.61), p < 0.001
Nocturnal confirmed hypoglycemia§, rate ratio	N/A	N/A	0.81 (0.35 to 1.90), NS	N/A	N/A	0.17 (0.10 to 0.31), p < 0.001
Daily insulin dose¶, ETD, U	–14.90 (–17.14 to 12.66), p < 0.0001	N/A	0.02 NS	N/A	N/A	41 dose steps vs 66 U p < 0.001

Values in square brackets indicate 95% CIs.

^† Change from baseline to end of trial (week 26).

^‡ Confirmed with plasma glucose <3.1 mmol/l.

^§Nocturnal confirmed hypoglycemia, plasma glucose <3.1 mmol/l occurring 00:01–05:59 inclusive.

^¶ At week 26.

ETD: Estimated treatment difference; IDegLira: Insulin degludec/liraglutide; N/A: Not applicable/available; NS: Not significant.